Literature DB >> 25995036

Getting personal: Head and neck cancer management in the era of genomic medicine.

Andrew C Birkeland1, Wendy R Uhlmann2,3,4, J Chad Brenner1,5, Andrew G Shuman1,4,5.   

Abstract

BACKGROUND: Genetic testing is rapidly becoming an important tool in the management of patients with head and neck cancer. As we enter the era of genomics and personalized medicine, providers should be aware of testing options, counseling resources, and the benefits, limitations, and future of personalized therapy.
METHODS: This article offers a primer to assist clinicians treating patients in anticipating and managing the inherent practical and ethical challenges of cancer care in the genomic era.
RESULTS: Clinical applications of genomics for head and neck cancer are emerging. We discuss the indications for genetic testing, types of testing available, implications for care, privacy/disclosure concerns, and ethical considerations. Hereditary genetic syndromes associated with head and neck neoplasms are reviewed, and online genetics resources are provided.
CONCLUSION: This article summarizes and contextualizes the evolving diagnostic and therapeutic options that impact the care of patients with head and neck cancer in the genomic era.
© 2015 Wiley Periodicals, Inc. Head Neck 38: E2250-E2258, 2016. © 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  cancer; ethics; genomics; head and neck; personalized medicine

Mesh:

Year:  2015        PMID: 25995036      PMCID: PMC4654712          DOI: 10.1002/hed.24132

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  70 in total

Review 1.  Accessing genetic variation: genotyping single nucleotide polymorphisms.

Authors:  A C Syvänen
Journal:  Nat Rev Genet       Date:  2001-12       Impact factor: 53.242

2.  Key Internet genetics resources for the clinician.

Authors:  Wendy R Uhlmann; Alan E Guttmacher
Journal:  JAMA       Date:  2008-03-19       Impact factor: 56.272

3.  Potential etiologic and functional implications of genome-wide association loci for human diseases and traits.

Authors:  Lucia A Hindorff; Praveen Sethupathy; Heather A Junkins; Erin M Ramos; Jayashri P Mehta; Francis S Collins; Teri A Manolio
Journal:  Proc Natl Acad Sci U S A       Date:  2009-05-27       Impact factor: 11.205

4.  Physicians' current practices and opportunities for DNA banking of dying patients with cancer.

Authors:  John M Quillin; Joann N Bodurtha; Laura A Siminoff; Thomas J Smith
Journal:  J Oncol Pract       Date:  2011-05       Impact factor: 3.840

Review 5.  Medullary thyroid carcinoma: ethical issues for the surgeon.

Authors:  Andrew G Shuman; Ashok R Shaha; R Michael Tuttle; Joseph J Fins; Luc G T Morris
Journal:  Ann Surg Oncol       Date:  2012-02-10       Impact factor: 5.344

6.  Patients' expectations about effects of chemotherapy for advanced cancer.

Authors:  Jane C Weeks; Paul J Catalano; Angel Cronin; Matthew D Finkelman; Jennifer W Mack; Nancy L Keating; Deborah Schrag
Journal:  N Engl J Med       Date:  2012-10-25       Impact factor: 91.245

7.  Ancillary care obligations of medical researchers.

Authors:  Neal Dickert; David Wendler
Journal:  JAMA       Date:  2009-07-22       Impact factor: 56.272

8.  American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility.

Authors: 
Journal:  J Clin Oncol       Date:  2003-04-11       Impact factor: 44.544

9.  COSMIC: exploring the world's knowledge of somatic mutations in human cancer.

Authors:  Simon A Forbes; David Beare; Prasad Gunasekaran; Kenric Leung; Nidhi Bindal; Harry Boutselakis; Minjie Ding; Sally Bamford; Charlotte Cole; Sari Ward; Chai Yin Kok; Mingming Jia; Tisham De; Jon W Teague; Michael R Stratton; Ultan McDermott; Peter J Campbell
Journal:  Nucleic Acids Res       Date:  2014-10-29       Impact factor: 16.971

10.  ACMG statement on direct-to-consumer genetic testing.

Authors: 
Journal:  Genet Med       Date:  2004 Jan-Feb       Impact factor: 8.822

View more
  13 in total

1.  Personalizing Medicine in Head and Neck Squamous Cell Carcinoma: The Rationale for Combination Therapies.

Authors:  Andrew C Birkeland; J Chad Brenner
Journal:  Med Res Arch       Date:  2015

2.  Differential compensation mechanisms define resistance to PI3K inhibitors in PIK3CA amplified HNSCC.

Authors:  Nicole L Michmerhuizen; Elizabeth Leonard; Aditi Kulkarni; J Chad Brenner
Journal:  Otorhinolaryngol Head Neck Surg       Date:  2016-06-07

Review 3.  The potential for tumor suppressor gene therapy in head and neck cancer.

Authors:  Andrew C Birkeland; Megan L Ludwig; Matthew E Spector; J Chad Brenner
Journal:  Discov Med       Date:  2016-01       Impact factor: 2.970

Review 4.  Moving towards personalised therapy in head and neck squamous cell carcinoma through analysis of next generation sequencing data.

Authors:  M Giefing; M Wierzbicka; K Szyfter; J C Brenner; B J Braakhuis; R H Brakenhoff; C R Bradford; J A Sorensen; A Rinaldo; J P Rodrigo; R P Takes; A Ferlito
Journal:  Eur J Cancer       Date:  2016-02-04       Impact factor: 9.162

5.  The genomic landscape of UM-SCC oral cavity squamous cell carcinoma cell lines.

Authors:  Megan L Ludwig; Aditi Kulkarni; Andrew C Birkeland; Nicole L Michmerhuizen; Susan K Foltin; Jacqueline E Mann; Rebecca C Hoesli; Samantha N Devenport; Brittany M Jewell; Andrew G Shuman; Matthew E Spector; Thomas E Carey; Hui Jiang; J Chad Brenner
Journal:  Oral Oncol       Date:  2018-11-08       Impact factor: 5.337

6.  Mutational profiles of persistent/recurrent laryngeal squamous cell carcinoma.

Authors:  Joshua D Smith; Andrew C Birkeland; Andrew J Rosko; Rebecca C Hoesli; Susan K Foltin; Paul Swiecicki; Michelle Mierzwa; Steven B Chinn; Andrew G Shuman; Kelly M Malloy; Keith A Casper; Scott A McLean; Gregory T Wolf; Carol R Bradford; Mark E Prince; John Chad Brenner; Matthew E Spector
Journal:  Head Neck       Date:  2018-12-12       Impact factor: 3.147

7.  Pathogenetic Analysis of Sinonasal Teratocarcinosarcomas Reveal Actionable β-catenin Overexpression and a β-catenin Mutation.

Authors:  Andrew C Birkeland; Sarah J Burgin; Megan Yanik; Megan V Scott; Carol R Bradford; Jonathan B McHugh; Scott A McLean; Stephen E Sullivan; Jacques E Nor; Erin L McKean; J Chad Brenner
Journal:  J Neurol Surg B Skull Base       Date:  2017-03-27

8.  Correlation of Crtc1/3-Maml2 fusion status, grade and survival in mucoepidermoid carcinoma.

Authors:  Andrew C Birkeland; Susan K Foltin; Nicole L Michmerhuizen; Rebecca C Hoesli; Andrew J Rosko; Serena Byrd; Megan Yanik; Jacques E Nor; Carol R Bradford; Mark E Prince; Thomas E Carey; Jonathan B McHugh; Matthew E Spector; J Chad Brenner
Journal:  Oral Oncol       Date:  2017-03-10       Impact factor: 5.337

9.  A review of drugs in development for the personalized treatment of head and neck squamous cell carcinoma.

Authors:  Andrew C Birkeland; Paul L Swiecicki; J Chad Brenner; Andrew G Shuman
Journal:  Expert Rev Precis Med Drug Dev       Date:  2016-07-15

10.  Patient and Provider Perspectives Regarding Enrollment in Head and Neck Cancer Research.

Authors:  Andrew G Shuman; Michele C Gornick; Collin Brummel; Madison Kent; Kayte Spector-Bagdady; Elliot Biddle; Carol R Bradford; J Chad Brenner
Journal:  Otolaryngol Head Neck Surg       Date:  2019-12-10       Impact factor: 5.591

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.